Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CanSeq: Whole-Exome Sequencing (WES) of Cancer Patients

NCT02127359 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02127359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02127359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CanSeq: Whole-Exome Sequencing (WES) of Cancer Patients
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2019
Enrollment
244 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, lung adenocarcinoma